Company intelligence / Profile preview

ObsEva SA

Geneva, Switzerland

Ownership: Public · OBSN
Development stage: Phase 3

Overview

ObsEva was a clinical-stage biopharmaceutical company developing novel therapies to improve women’s reproductive health, with a focus on conditions such as uterine fibroids, endometriosis, preterm labor, and infertility. Its lead asset was nolasiban for improving pregnancy rates in IVF. The company faced financial difficulties and began winding down operations in early 2024 after unsuccessful attempts to monetize its assets and maintain listing status.

Therapeutic areas: Women's Health
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ebopiprant

Financials

Market cap: $109.6M
Total revenue: $2.6M

Beyond the preview

Go deeper on ObsEva SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ObsEva SA.

Explore the full profile